Technology Networks – Analytical Cannabis’ sister publication – spoke to the team at Delix Therapeutics' to learn how their drugs can keep the benefits of psychedelics compounds while leaving behind the trip.
The credibility watchdog praised Analytical Cannabis’ dedication to fact-based reporting of cannabis industry events and relevant scientific research.
While these psychedelics users did tend to report an increased belief in the paranormal after their trip, superstitious beliefs largely remained unchained.
Analytical Cannabis rounds up the year’s top cannabis stories, with a particular focus on research and testing.
The first-of-its-kind phase 3 trial will soon begin in the UK to test whether ketamine can help treat patients with alcohol use disorder.
Dr. Perkins spoke with Technology Networks – the sister publication of Analytical Cannabis – to provide context on the latest research study and the next steps for the research group.
Stephen Wright breaks down the lengthy process of getting a psychedelic medicine approved in the US.
Acute physical health adverse effects were reported by 69.9% of the study's participants.
Dr. Markus Roggen, president and chief science officer of Vancouver-based Delic Labs, delves into the less favorable side of psychedelic research.